{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/acne-vulgaris/how-this-topic-was-developed/evidence-exclusion-criteria/","result":{"pageContext":{"chapter":{"id":"10179a08-abca-5ecd-982e-b1147cb710a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria","depth":2,"htmlHeader":"<!-- begin field c9bfb8c0-174a-49c6-8c80-a7f20187bfcc --><h2>Evidence exclusion criteria</h2><!-- end field c9bfb8c0-174a-49c6-8c80-a7f20187bfcc -->","summary":null,"htmlStringContent":"<!-- begin item 5486ba78-c7ef-4589-85d4-a7f20187a3cf --><!-- begin field b6bb08bd-29f1-491f-bf59-a7f20187bfcc --><h2>Our policy</h2><!-- end field b6bb08bd-29f1-491f-bf59-a7f20187bfcc --><!-- begin field daa8129f-0b5b-4b35-9c42-a7f20187bfcc --><p>Scoping a literature search, and reviewing the evidence for CKS is a methodical and systematic process that is carried out by the lead clinical author for each topic. Relevant evidence is gathered in order that the clinical author can make fully informed decisions and recommendations. It is important to note that some evidence may be excluded for a variety of reasons. These reasons may be applied across all CKS topics or may be specific to a given topic.</p><p>Studies identified during literature searches are reviewed to identify the most appropriate information to author a CKS topic, ensuring any recommendations are based on the best evidence. We use the principles of the GRADE and PICOT approaches to assess the quality of published research. We use the principles of AGREE II to assess the quality of published guidelines.</p><!-- end field daa8129f-0b5b-4b35-9c42-a7f20187bfcc --><!-- begin field 1e4c9a92-ffde-4e37-81a2-a7f20187bfcc --><h2>Standard exclusions for scoping literature:</h2><!-- end field 1e4c9a92-ffde-4e37-81a2-a7f20187bfcc --><!-- begin field c3222cfe-7669-4e17-8961-a7f20187bfcc --><ul><li>Animal studies</li><li>Original research is not written in English</li></ul><!-- end field c3222cfe-7669-4e17-8961-a7f20187bfcc --><!-- begin field badf2bfd-51c2-4113-8d28-a7f20187bfcc --><h2>Possible exclusions for reviewed literature:</h2><!-- end field badf2bfd-51c2-4113-8d28-a7f20187bfcc --><!-- begin field e93464f5-5a46-4755-a951-a7f20187bfcc --><ul><li>Sample size too small or study underpowered</li><li>Bias evident or promotional literature</li><li>Population not relevant</li><li>Intervention/treatment not relevant</li><li>Outcomes not relevant</li><li>Outcomes have no clear evidence of clinical effectiveness</li><li>Setting not relevant</li><li>Not relevant to UK</li><li>Incorrect study type</li><li>Review article</li><li>Duplicate reference</li></ul><!-- end field e93464f5-5a46-4755-a951-a7f20187bfcc --><!-- end item 5486ba78-c7ef-4589-85d4-a7f20187a3cf -->","topic":{"id":"4f10413c-64a7-5bb3-9003-1093b58e5700","topicId":"7737f6eb-1907-461e-a10b-166056e652b7","topicName":"Acne vulgaris","slug":"acne-vulgaris","lastRevised":"Last revised in August 2020","chapters":[{"id":"c13b5a16-bcf3-5b36-8dce-af226250264d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"318cce93-72af-5473-9c96-2577e69df14c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6aac7922-c920-5394-bc2c-08ae3e93e4c5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b6ea59d7-e11c-59ba-ae3a-d12eda1c224b","slug":"changes","fullItemName":"Changes"},{"id":"501eff80-f5ab-5966-b79a-791cec9fcf7c","slug":"update","fullItemName":"Update"}]},{"id":"017f5393-8a9f-5cdb-9799-d9c32c6b50e9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"32769738-e7d1-5c7a-a6ac-7e242b6ad659","slug":"goals","fullItemName":"Goals"},{"id":"60cde7a9-d789-5629-a7d6-e14882c6caf9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f91e328f-4d37-5a01-ab6d-edf7165acdaf","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01961474-a4a0-5330-bc03-aca2c93fd7ed","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"867bb680-22ea-5d29-88b0-f219f9e8dae8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8447443c-c6e1-5af4-ab33-68aa460c97b0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"10279ff1-6a1f-5af9-97b1-73405139911f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13ced928-40f6-593c-8ae8-3d619c885e2e","slug":"definition","fullItemName":"Definition"},{"id":"290d67e9-4d5f-5a03-bafc-46380a14e964","slug":"causes","fullItemName":"Causes"},{"id":"2c90cfb7-ff4f-535b-b067-7b291de8de21","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5665dddd-4418-59f5-8480-8d73bc88b392","slug":"complications","fullItemName":"Complications"},{"id":"8e63da8e-8783-584a-962f-77fc8f5cda7c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cac20ff4-4d28-5a3d-ab66-5ad66ea6485d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"318b12a5-f38e-5aa0-866d-258e0bc4606b","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"00cb6f19-98f0-5279-8ca3-56e9898a856b","slug":"assessment","fullItemName":"Assessment"},{"id":"9a6b352b-2522-507b-baee-3746ed6c5fc1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"93060cf3-048d-55d8-b979-1ee7c8b333d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"8708236c-483d-548a-bcbb-ece4a63d3ef2","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"}]},{"id":"ff879f6d-4cca-54e7-b137-1bea3673664f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9958ec-2ef2-5cdd-8066-9039ba251071","slug":"benzoyl-peroxide","fullItemName":"Benzoyl peroxide"},{"id":"6d9ac0d3-8378-55b8-b6dc-17fb87472c20","slug":"topical-retinoids","fullItemName":"Topical retinoids"},{"id":"b3431b25-388f-5ae4-9ae3-fe13143c5d26","slug":"topical-antibiotics","fullItemName":"Topical antibiotics"},{"id":"9ca57669-ad06-5179-885d-5b8063e1323f","slug":"azelaic-acid","fullItemName":"Azelaic acid"},{"id":"8ae4cfcf-ffa5-5d2f-b469-369a52c50963","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"dd897071-f76b-5e49-9c2d-e98f4b853afa","slug":"combined-oral-contraceptives","fullItemName":"Combined oral contraceptives"}]},{"id":"1a455bee-cdcd-5bfe-ac3c-92ebf7dc4f1b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c326d983-7898-5757-a2dd-0324dc5bca9a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7efc9e19-3f3c-5fe4-86af-6645e982294d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5133582b-9a2b-5faf-a3be-a014b639deef","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"10179a08-abca-5ecd-982e-b1147cb710a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25e71f93-96a6-5694-a7be-371938647a37","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2adb6ee6-1991-50db-bb70-4a7b3d113064","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9f2f3c9d-3968-50fd-88cb-555214f14d6b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c326d983-7898-5757-a2dd-0324dc5bca9a","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}